Shared from twixb · endpts.com
Avalyn Pharma has launched a $300 million upsized IPO, selling over 16.5 million shares at $18 each. Additionally, Alector has terminated another study in its partnership with GSK.
Avalyn Pharma's successful upsized IPO, raising $300 million, highlights a strong market interest in biotech investments, signaling potential opportunities for stakeholders in healthtech and biotech to explore IPO strategies or partnerships with companies showing robust investor confidence.
Powered by twixb
twixb tracks your favorite blogs and social media, filters by keywords, and delivers personalized key learnings — straight to your inbox.
Recent stories curated alongside this one.
Novo Nordisk has secured a partnership for its early-stage Parkinson's cell therapy, while also announcing label expansions for two drugs aimed at rare diseases. Additionally, Genmab has discontinued a Phase 1 cancer trial.
Inhibrx, a biotech company based in San Diego, reports that its experimental drug INBRX-106, when combined with Merck's Keytruda, was more effective in shrinking tumors in patients with metastatic head cancer than Keytruda alone.
The FDA is facing potential leadership changes with questions about Commissioner Marty Makary's future, while there are developments in a revived gene therapy for a rare disease and disappointing adoption rates for Alzheimer's drugs.
Inhibrx Biosciences' OX40 agonist combined with Keytruda significantly increased response rates in a midphase clinical trial, prompting the biotech to move forward with the program, which has garnered interest from Merck & Co.
Enterprise Therapeutics' cystic fibrosis drug candidate has successfully met its primary endpoint in a phase 2 trial, advancing the company's efforts in a field previously explored by other firms like Vertex.
